We use cookies to analyze site traffic and improve your experience.
By accepting, you consent to the use of analytics cookies.

TPCS:NASDAQTechPrecision Corporation Analysis

Data as of 2026-07-30 - not real-time

$4.41

Latest Price

8/10Risk

Risk Level: High

Executive Summary

TechPrecision (TPCS) is trading at $4.41, barely above its calculated support of $4.41 and well below its 20‑day SMA of $4.73, indicating a fragile price base. The MACD histogram is negative and the signal line is bearish, while RSI sits at 46, suggesting neutral momentum but no near‑term upside. Volume is on a decreasing trend, and the 30‑day volatility is an elevated 71%, reflecting a highly erratic price action. Fundamentally, the company posts negative margins (‑5.3% profit margin) and a steep revenue decline of 14.7%, yet the forward PE of 2.79 is dramatically below the industry average of 30, hinting at a potential valuation discount if the business can reverse its earnings trajectory.
The balance sheet is strained with a debt‑to‑equity ratio of 137 and a cash balance of only $0.45 M against $10.55 M of debt, while free cash flow is deeply negative. No dividend is paid, and the Fear & Greed Index sits at “Extreme Greed,” which may be inflating speculative buying despite the company’s operational challenges. Recent news flags heightened short‑interest pressure, adding to the downside risk.

Market Outlook

Short Term

< 1 year
Cautious
Model confidence: 7/10

Key Factors

  • Price flirting with key support and below short‑term moving averages
  • Bearish MACD signal and decreasing volume
  • High short‑interest pressure from recent news

Medium Term

1–3 years
Neutral
Model confidence: 5/10

Key Factors

  • Forward earnings estimate positive with a low forward PE
  • Severe debt load and negative cash flow limiting operational flexibility
  • Neutral technical stance with no clear breakout direction

Long Term

> 3 years
Neutral
Model confidence: 5/10

Key Factors

  • Exposure to defense and aerospace contracts offering stable demand
  • Potential upside if the company can improve margins and restructure debt
  • Persistent financial weakness and high volatility tempering optimism

Key Metrics & Analysis

Financial Health

Revenue Growth-14.70%
Profit Margin-5.26%
P/E Ratio2.8
ROE-20.28%
ROA-2.03%
Debt/Equity137.47
P/B Ratio5.8
Op. Cash Flow$6.0K
Free Cash Flow$-1117000
Industry P/E30.3

Technical Analysis

TrendNeutral
RSI46.2
Support$4.41
Resistance$5.35
MA 20$4.72
MA 50$4.23
MA 200$4.28
MACDBearish
VolumeDecreasing
Fear & Greed Index84.54

Valuation

GradeUndervalued
TypeValue

Risk Assessment

Beta0.63
Volatility71.25%
Sector RiskMedium
Reg. RiskMedium
Geo RiskLow
Currency RiskLow
Liquidity RiskMedium

This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.